title: Comparison of antinociception induced by supraspinally administered L-arginine and kyotorphin.
abstract: 1. Intracerebroventricular (i.c.v.) or intracisternal (i.cist.) administration of kyotorphin (KTP), an endogenous Met-enkephalin releaser, at 5 micrograms per mouse, and L-arginine (L-Arg), a possible KTP precursor, at 30 micrograms per mouse, elicited antinociception in mice to a similar extent, as assessed by the tail-flick test. 2. Intracisternal preadministration of anti-KTP serum abolished the effect of i.cist. KTP and i.c.v. or i.cist. L-Arg, but not of i.c.v. KTP. 3. The antinociceptive effects of i.cist. KTP and of i.c.v. or i.cist. L-Arg disappeared in reserpinized mice, whereas the effect of i.c.v. KTP was unaffected by treatment of mice with reserpine. 4. Intrathecal (i.t.) phentolamine markedly reduced the antinociception induced by i.cist. KTP and by i.c.v. or i.cist. L-Arg, but not by i.c.v. KTP. 5. Intrathecal methysergide attenuated the antinociceptive effects of i.cist. KTP, but not of i.c.v. KTP and i.c.v. or i.cist. L-Arg. 6. These results suggest that the antinociception produced by i.cist. KTP, but not by i.c.v. KTP, is mediated by the brainstem-spinal noradrenergic and 5-hydroxytryptaminergic systems, and that L-Arg given i.c.v. or i.cist. increases KTP formation in the lower brain, possibly the brainstem, resulting in antinociception mediated by the descending noradrenergic system. Therefore, the regional distribution of KTP receptors and KTP synthetase in the brain does not appear to be common.
authors.affiliation: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Kinki University, Higashi-Osaka, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Kawabata
authors.forename: S
authors.initials: S
authors.lastname: Manabe
authors.forename: H
authors.initials: H
authors.lastname: Takagi
mesh_terms: D000700:Analgesics / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D001933:Brain Stem / Q000502:physiology; D002946:Cisterna Magna; D004723:Endorphins / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D007267:Injections; D007276:Injections, Intraventricular; D008297:Male; D008784:Methysergide / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D009638:Norepinephrine / Q000502:physiology; D010147:Pain Measurement / Q000187:drug effects; D010646:Phentolamine / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D012701:Serotonin / Q000502:physiology; D013116:Spinal Cord / Q000502:physiology
chemical_list: D000700:Analgesics; D004723:Endorphins; C019448:kyotorphin; D012701:Serotonin; D012110:Reserpine; D001120:Arginine; D009638:Norepinephrine; D008784:Methysergide; D010646:Phentolamine